Low-Dose Naltrexone: Regret, Stopping, and Restarting, What Real Users and Clinical Data Actually Show

What LDN is and how well it is studied

Low-dose naltrexone means naltrexone at 0.5 to 6 mg a day, most often 4.5 mg, used off-label for conditions such as fibromyalgia, multiple sclerosis, Crohn's disease and long COVID, and commonly made by compounding pharmacies [1][3]. No FDA-approved low-dose product exists, and FDA says it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [3]. A 2026 narrative review screened 105 studies, 15 of them randomized controlled trials, with the rest mostly case reports, case series and observational studies; it also notes that inconsistencies in compounded formulations add uncertainty [1].

The studies below report side effects, pain scores, quality-of-life scores and withdrawals during treatment. They do not show how often people regret stopping LDN or which restart dose works best.

Side effects reported in trials

The 2026 review describes LDN as generally safe and well tolerated, with trial effects mostly mild and transient, most often insomnia, vivid dreams, nausea and dizziness [1].

A meta-analysis of four randomized fibromyalgia trials (222 patients) found more vivid dreams and nausea with LDN than with placebo, and no significant difference in serious adverse events [7]. In the 12-month INNOVA trial, 33 of 48 women on LDN (68.8%) and 36 of 50 on placebo (72%) reported adverse events, mostly mild and transient, with no treatment-related serious events [6].

Not every trial saw a problem. In the 31-woman fibromyalgia crossover published in 2013, LDN was rated as tolerable as placebo and no serious side effects were reported [8]. The earliest fibromyalgia pilot, 10 women, called insomnia and vivid dreams rare, minor and transient [9]. The 2007 open-label Crohn's study of 17 patients named sleep disturbance as the most common side effect, in 7 of them [10].

What happens when you stop

The naltrexone tablet label states that the drug does not lead to physical or psychological dependence, and that tolerance to its opioid-blocking effect is not known to occur [2]. The labels were written for 50 mg tablets and 380 mg injections and give no guidance on LDN doses, and no LDN-specific data on stopping or restarting are in the studies cited here [1][2].

Rebound is a separate question, and the data are thin. The 2007 open-label Crohn's study re-checked patients four weeks after a 12-week course ended and reported that Crohn's Disease Activity Index scores remained lower than baseline [10]. That is 17 people, uncontrolled.

The labels' warning runs the other way. After naltrexone treatment ends, opioid tolerance is lower than before treatment, so a previously tolerated opioid dose can cause life-threatening intoxication, and fatal overdoses have been reported after discontinuing treatment [2][11]. The labels advise strongly considering a prescription for an opioid overdose reversal agent such as naloxone or nalmefene [2][11].

Restarting: the opioid question comes first

Naltrexone is contraindicated in patients receiving opioid analgesics, in patients currently dependent on opioids (including those maintained on methadone or buprenorphine), in patients in acute opioid withdrawal, and in anyone with a positive urine screen for opioids or a failed naloxone challenge [2][11]. The contraindication for people receiving opioid analgesics is written without any dose exception [2].

The tablet label recommends an opioid-free interval of at least 7 to 10 days for patients previously dependent on short-acting opioids, and says people transitioning from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [2]. The Vivitrol label gives the same 7 to 10 day minimum [11].

The tablet label describes precipitated withdrawal as usually appearing within 5 minutes of ingestion and lasting up to 48 hours, with mental status changes including confusion, somnolence and visual hallucinations, fluid losses from vomiting and diarrhea needing intravenous fluids, and postmarketing cases that required hospital admission and sometimes intensive care [2].

Opioids here means more than pain prescriptions. The label names opioid-containing cough and cold preparations and opioid antidiarrheals [2]. For other drugs, the tablet label says studies of interactions between naltrexone and non-opioid drugs have not been performed, so caution is advised with any concomitant drug [2].

What the trials found on benefit

Fibromyalgia. The result that built LDN's reputation came from a crossover trial of 31 women: pain fell 28.8% on 4.5 mg naltrexone against 18.0% on placebo (P=0.016), and 32% of participants met the trial's response criteria on LDN against 11% on placebo (P=0.05); fatigue and sleep did not improve [8]. Larger placebo-controlled trials did not reproduce it. In a 58-patient crossover, the Fibromyalgia Impact Questionnaire score differed by a median of -1.65 points (P=0.3) and summed pain ratings by -0.33 (P=0.4), and the authors concluded the data did not indicate clinically relevant analgesic efficacy [5]. In a 99-woman trial of 6 mg daily, pain fell 1.3 points on LDN and 0.9 on placebo, a between-group difference of -0.34 (95% CI -0.95 to 0.27, p=0.27) [4]. In the 12-month INNOVA trial of 98 women on 4.5 mg, pain changed -0.33 points on LDN and -0.64 on placebo at three months, an adjusted difference of 0.49 (p=0.236) [6]. A meta-analysis of four trials and 222 patients found a small pain reduction with LDN (mean difference -0.86, 95% CI -1.20 to -0.51) but no significant difference on the Fibromyalgia Impact Questionnaire [7].

Crohn's disease. A randomized placebo-controlled trial of 40 adults with active Crohn's disease found a fall of 70 points or more on the Crohn's Disease Activity Index in 88% of those on 4.5 mg naltrexone against 40% on placebo (p=0.009), an endoscopic response in 78% against 28% (p=0.008), and remission by endoscopy score in 33% against 8% over 12 weeks [12]. It is one small trial.

Multiple sclerosis. In an 8-week crossover pilot, 80 people were enrolled and 60 completed; high dropout and data errors reduced the trial's power. LDN 4.5 mg nightly improved the SF-36 Mental Component Summary by 3.3 points (p=0.04) and the Mental Health Inventory by 6 points (p<0.01), and was well tolerated with no serious adverse events [13]. A separate 17-week trial in 96 adults with relapsing-remitting or secondary progressive MS found no meaningful difference between groups in pain, energy, emotional well-being, social or cognitive function, or overall quality of life, though health perception scores differed between groups [14].

Long COVID. A systematic review searching to 5 May 2026 identified no randomized trials; it pooled four uncontrolled before-and-after studies (155 people, 1 to 6 mg a day) that showed improvements in fatigue, brain fog, sleep, pain and daily functioning, which uncontrolled data cannot separate from placebo [15].

The overall verdict. The 2026 review found that early positive findings from uncontrolled studies were rarely confirmed in placebo-controlled trials and concluded that current evidence does not support routine clinical use, while describing LDN as low-risk and possibly worth trying in treatment-resistant cases if its experimental status is explained [1].

HealthRX.com offers low-dose naltrexone as a compounded prescription.